SMI Expanded

SMI Expanded handeln
1.855,03 PKT +5,46 PKT +0,30 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

ISIN CH0019399861


Analysen zu SMI Expanded-Werten

Datum Rating Analyst
03.02.12 Roche overweight Barclays Capital
03.02.12 Givaudan neutral UBS AG
03.02.12 Logitech neutral Sarasin Research
02.02.12 Roche neutral Nomura
01.02.12 UBS neutral Banc of America Securities-Merrill Lynch
01.02.12 UBS buy Banc of America Securities-Merrill Lynch
01.02.12 Roche buy Banc of America Securities-Merrill Lynch
01.02.12 Swatch (I) buy Goldman Sachs Group Inc.
01.02.12 Holcim neutral J.P. Morgan Cazenove
01.02.12 Holcim neutral J.P. Morgan Cazenove
01.02.12 ABB (Asea Brown Boveri) overweight J.P. Morgan Cazenove
01.02.12 UBS underperform Cheuvreux SA
01.02.12 Roche buy Sarasin Research
01.02.12 ABB (Asea Brown Boveri) outperform Sanford C. Bernstein and Co., Inc.
31.01.12 Holcim sell Goldman Sachs Group Inc.
31.01.12 Roche overweight J.P. Morgan Cazenove
31.01.12 ABB (Asea Brown Boveri) buy Citigroup Corp.
31.01.12 ABB (Asea Brown Boveri) outperform Exane-BNP Paribas SA
31.01.12 Nestlé kaufen Hamburger Sparkasse AG (Haspa)
31.01.12 ABB (Asea Brown Boveri) halten Independent Research GmbH
31.01.12 Novartis neutral Goldman Sachs Group Inc.
31.01.12 Nestlé outperform Cheuvreux SA
31.01.12 Zurich Insurance buy Nomura
31.01.12 Nestlé overweight J.P. Morgan Cazenove
30.01.12 Novartis kaufen Hamburger Sparkasse AG (Haspa)
30.01.12 Barry Callebaut sell Société Générale Group S.A. (SG)
30.01.12 SGS SA neutral Sarasin Research
27.01.12 UBS underperform Exane-BNP Paribas SA
27.01.12 UBS underperform Exane-BNP Paribas SA
27.01.12 Holcim sell Citigroup Corp.
27.01.12 Logitech neutral Citigroup Corp.
27.01.12 Novartis outperform Credit Suisse Group
27.01.12 Novartis buy Société Générale Group S.A. (SG)
26.01.12 Roche overweight Barclays Capital
26.01.12 Zurich Insurance halten Independent Research GmbH
26.01.12 Logitech neutral Sarasin Research
26.01.12 Novartis underperform Cheuvreux SA
25.01.12 Roche outperform Exane-BNP Paribas SA
25.01.12 Holcim neutral UBS AG
25.01.12 Novartis buy WestLB AG